White Paper

IND Ready Is Not Phase 2 Ready

Download

Download White Paper

The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.

Share

Related Resources

All Resources

The New Chemistry, Manufacturing, and Controls (CMC) Regulations in China, Syner-G

white-paper

The New Chemistry, Manufacturing, and Controls (CMC) Regulations in China

Read More

Person in protective gloves handling small medical vials or samples in a lab setting

post

Why FDA PreCheck is a game-changer for small & mid-sized pharma — and how these companies should lean in

Read More

Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS), Syner-G

white-paper

Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS): Complementary or Competitive Processes?

Read More

BioPharma Due Diligence in a Shifting Global Market, Syner-G

white-paper

BioPharma Due Diligence in a Shifting Global Market

Read More

Let's move from science to success.